JPMorgan Chase & Co. Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price

Replimune Group (NASDAQ:REPL - Free Report) had its price target increased by JPMorgan Chase & Co. from $16.00 to $18.00 in a research report released on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

REPL has been the subject of a number of other reports. HC Wainwright upped their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. BMO Capital Markets upped their price target on shares of Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Finally, Jefferies Financial Group upped their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, December 4th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $19.43.

Replimune Group Trading Up 0.3 %

Shares of NASDAQ REPL traded up $0.04 during trading on Wednesday, hitting $12.68. 952,417 shares of the company traded hands, compared to its average volume of 737,730. Replimune Group has a 1 year low of $4.92 and a 1 year high of $17.00. The company has a 50-day moving average price of $12.79 and a 200-day moving average price of $11.99. The firm has a market capitalization of $976.55 million, a P/E ratio of -4.13 and a beta of 1.30. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14.

Remove Ads

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, equities analysts predict that Replimune Group will post -2.97 EPS for the current year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the company's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares of the company's stock, valued at $2,509,013.88. This represents a 4.72 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 8.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sterling Capital Management LLC boosted its position in Replimune Group by 364.5% in the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after buying an additional 1,655 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Replimune Group by 696.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after purchasing an additional 5,922 shares in the last quarter. Aster Capital Management DIFC Ltd raised its stake in shares of Replimune Group by 8,798.9% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after purchasing an additional 8,183 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Replimune Group in the 4th quarter valued at about $117,000. Finally, Quantinno Capital Management LP acquired a new stake in shares of Replimune Group in the 4th quarter valued at about $127,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.